David Heppner
Company: University at Buffalo
Job title: Assistant Professor - Medicinal Chemistry
Seminars:
Structural Insights into Emerging Inhibitors Targeting EGFR Mutations 12:00 pm
The structure of lazertinib allows for enhanced potency and mutant selectivity against EGFR T790M Next generation mutant EGFR C797S inhibitors bind the kinase domain through H-bonding with conserved catalytic residues Spanning ATP-allosteric EGFR inhibitors can be developed exhibiting unique kinase domain binding and mutant selectivityRead more
day: Day Two